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ABSTRACT 
Background 
Individuals with methamphetamine use disorder (MUD) frequently present with psychiatric 
comorbidities with impulsive features.  Little research has been conducted on comorbidity with 
impulsive features in MUD.  Therefore, this cross-sectional study aimed to delineate comorbid 
disorders with impulsivity in adult patients with a primary diagnosis of MUD.   
 
Methods 
Participants with lifetime MUD were included.  Well established measures screened for comorbid 
psychiatric disorders with impulsive features.  Illness severity was measured by the Yale Brown 
Obsessive-Compulsive Scale – adapted for drug use.  The UPPS-P Impulsive Behavior Scale was 
used to assess impulsivity levels.  A cluster analysis (CA) of lifetime comorbid disorders with 
impulsive features was performed. Demographic and clinical correlates of each identified cluster were 
identified. 
 
Results  
Sixty five (n = 65) adults with a primary diagnosis of MUD took part in the study.  They were 
predominantly female (44 females; 21 males), with ages ranging between 18 and 44 years (mean = 
30 years; SD = 6.53).  The CA rendered 4 groups.  Cases (n=12) in the “alcohol cluster” presented 
with AUD as their only impulsive disorder other than MUD.  Cases (n=19) in the “healthy cluster” had 
no comorbidity.  Cases (n=15) in the “antisocial cluster” all had comorbid antisocial personality 
disorder as well as polysubstance use disorders.  Cases (n=19) in the “borderline cluster” had 
borderline personality disorder and polysubstance use disorders.  Illness severity (Y-BOCS-du: 
p=0.03) and impulsivity levels (UPPS-P: p=0.01) differed significantly between the clusters.  The 
“alcohol cluster” had the highest illness severity and the “antisocial cluster reported the highest levels 
of impulsivity.   
 
Conclusion  
The findings of this contribute to the paucity data on impulsivity in MUD and may have implications for 
treatment.  Understanding how these conditions cluster in MUD, and remaining cognizant of the 
demographic and clinical correlates of each cluster in MUD, could potentially enable clinicians to 
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identify patients who are at higher risk for engaging in risky behaviors rendering them more vulnerable 
to treatment non-adherence or relapse 
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CHAPTER ONE 
INTRODUCTION 
Introduction 
This chapter provides a literature review of current knowledge on methamphetamine use disorder 
(MUD) and psychiatric disorders characterised by impulsive features.  In addition, the main focus of 
the research project is highlighted, including a rationale for the study, objectives and hypotheses, and 
a suggestion for a target journal for publication of this work.  
 
Context 
Methamphetamine (MA) use seems to be increasing globally (Akindipe, Wilson, & Stein, 2014).  It has 
reached epidemic proportions in South Africa, particularly in the Western Cape Province (Dada et al., 
2016; Dada, Burnhams, et al., 2017; Plüddemann et al., 2013) where early adulthood (Meade et al., 
2012), low educational levels (Meade et al., 2012; Semple, Zians, Grant, & Patterson, 2005; Watt et 
al., 2014) and mixed ancestry (Akindipe et al., 2014; Chetty, 2015; Harker et al., 2008) have been 
identified as risk factors for MA use.  A large majority of those who use MA develop 
methamphetamine use disorder (MUD).  
Methamphetamine use disorder is a psychiatric condition, classified as one of the substance-
related and other addictive disorders in the Diagnostic and Statistical Manual of Mental Disorders (fifth 
edition) (DSM-5) (American Psychological Association (APA), 2013).  Typical of MUD is the repeated 
unsuccessful attempts to cut down or stop using the drug, and clinically significant distress and 
functional impairment in several domains of life (APA, 2013).  For example, individuals with MUD 
often neglect major obligations such as work, studies, family and even recreational- and other 
important social activities (APA, 2013).  In addition, in MUD there is often a disregard of negative 
consequences that may affect the user or others (Brewer & Potenza, 2008; Fineberg et al., 2014).  
Individuals with MUD often spend vast amounts of time to obtain, use or recover from the effects of 
MA – even in hazardous situations (APA, 2013).  Additionally, MUD has been linked with problematic 
impulse control (Brooks et al., 2017; Terzi et al., 2017; Verdejo-García, Lawrence, & Clark, 2008).  
According to Mahoney et al. (2015) and Hoffman et al. (2006), patients with MUD score significantly 
higher in impulsivity assessments compared to healthy controls.  In comparison to users of other 
stimulant use disorders (e.g. cocaine use disorder), patients with MUD also score higher on 
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impulsivity assessments (Winhusen et al., 2013).  While methamphetamine and cocaine are both 
stimulants, they have some key differences that could lead to different impulsivity profiles in their 
users.  One key difference entails the relative length of subjective effects, which is considerably 
shorter for cocaine (Winhusen et al., 2013).  In addition, it has been shown that users of MA and 
users of cocaine are both impaired on cognitive measures (e.g., perceptual speed, manipulation of 
information, verbal recall) between methamphetamine- and cocaine users, but the type and degree of 
impairments are somewhat different (Winhusen et al., 2013; Sim et al., 2001). Many overlapping 
definitions of impulsivity exist.  For example, impulsivity has been defined as a trait leading to 
behavioral actions which are poorly planned or conceived, prematurely expressed, unduly risky, or 
inappropriate to the situation, and undesirable consequences usually result (Robbins, Gillan, Smith, 
Wit, & Ersche, 2012; Semple, Zians, Grant, & Patterson, 2005).  This is partly consistent with DSM-5 
(APA, 2013) which describes impulsivity as the actions that occur in the spur of the moment, hastily, 
and without forethought.  These impulsive actions, typically seen in MUD, have high potential for harm 
to oneself or to others.  Sensitivity to reward anticipation, delay aversion and poor planning are also 
typical of impulse dyscontrol (Hamilton et al., 2015; Pattij & Vanderschuren, 2008; Robbins et al., 
2012; Roháriková, 2016; Semple et al., 2005) and may be reflected in the desire for immediate 
rewards and without the ability to delay gratification; or in social intrusiveness, such as interrupting 
others excessively; or in making important decisions without considering the long-term consequences 
that may often turn out to be problematic (APA, 2013). Whereas some authors has suggested that 
impulsivity may be adaptive in some circumstances, it is generally regarded as a dysfunctional trait 
that can be associated with actions that are antisocial, destructive or harmful to self or others, and 
inappropriate to accepted social standards (Verdejo-García et al., 2008).  It is a complex 
phenomenon, and as can be seen from the previous definitions, problematic for the individual on 
multiple levels.  Impulsivity may increase the likelihood of using stimulant drugs which in turn may 
increase impulsivity, leading to potentially hazardous use - a vicious cycle indeed.  In other words, 
individuals with impulsive features may be at higher risk to experiment with MA, and MA use in turn is 
associated with increased impairment of behavioral control or impulsivity.  The role of impulsivity as a 
precursor to developing a SUD, and also as a consequence of chronic drug use, has become 
apparent in recent literature (e.g. Lanesman et al, 2019).   
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Various authors report psychiatric comorbidity in MUD (Morisano, Babor, & Robaina, 2014; 
Plüddemann et al., 2013; Warden et al., 2016).  According to Akindipe et al. (2014) and Harker et al. 
(2008), psychiatric disorders may also be more prevalent in MA-using individuals compared to the 
general population.  Mania and hypomania are frequently found among patients with MUD (Akindipe 
et al., 2014).  Lin et al. (2004) found that comorbid polysubstance use and SUDs are prevalent in MA 
users and Salo et al. (2011) identified that almost 60% of patients with MUD have a comorbid SUD.  
Substance use disorders in MUD range from alcohol use disorder (AUD), other stimulant use 
disorders (such as cocaine), cannabis, and sedative hypnotics and anxiolytics (Salo et al., 2011) 
(such as methaqualone / mandrax).  Lin et al. (2004) also found that “behavioral addictions” such as 
gambling disorder (GD) is sometimes seen in the MUD population.  Furthermore it is well documented 
that personality disorders such as antisocial personality disorder (ASPD) and borderline personality 
disorder (BPD) frequently occur in MUD (Plüddemann et al., 2013).  These disorders co-occurring 
with MUD may have strong links to impulsivity (Dawe, Gullo, & Loxton, 2004).  In conclusion, MUD is 
a psychiatric condition associated with impulsive features, and often co-occurs with disorders also 
characterized by impulsivity. 
 
Study Rationale 
Little research has been conducted on MUD and psychiatric comorbidity with impulsive features.  
Also, the research that does exist has been in the context of drug use in developed countries, with 
few studies having been conducted in low resource settings like South Africa (SA) (Lanesman et al., 
2019).  This study responded to recent pleas that highlighted the need for further research on MA use 
in South Africa - as a matter of social development, safety and public health (Mushanyu, Nyabadza, & 
Stewart, 2015; Watt et al., 2014; Wyk & Stuart, 2011).  According to the most recent report by the 
South African Community Epidemiology Network on Drug Use (SACENDU), the Western Cape 
Province where this study was conducted, has the highest prevalence of MUD of all provinces in 
South Africa (Dada, Erasmus, et al., 2017), making this an ideal location for this research endeavor.   
Furthermore, it appears that few studies exist on impulsive comorbidity in this population 
(Glasner-Edwards et al., 2008; Shoptaw, Peck, Reback, & Rotheram-Fuller, 2003).  
Methamphetamine use disorder is associated with significant mental health problems (Akindipe et al., 
2014; Weybright, Caldwell, Wegner, Smith, & Jacobs, 2016) and psychiatric comorbidities may 
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arguably be seen as a predisposition for, or a consequence of, continued drug use (Yen & Chong, 
2006).  Many psychiatric disorders are characterized by impulsivity and often feature in patients with 
MUD.  .   
Therefore the primary aim of the study was to delineate disorders characterized by impulsivity 
in a sample of adult patients with a primary diagnosis of MUD by means of a cluster analysis (Ward’s 
method) (CA), and to explore the demographic and clinical correlates of each identified cluster.  
Cognizance of the theses correlates of impulsivity in MUD can enable clinicians to identify patients 
who are at high risk for engaging in risky behaviors such as sexual promiscuity, rendering them more 
vulnerable to treatment non-adherence or relapse, or other difficulties such as HIV or sexually 
transmitted infections (e.g. Winhusen et al., 2013).  The investigation may thus potentially guide 
treatment, and ultimately improve outcome in these patients.   
 
The identified objectives and hypotheses were as follow: 
Objective 1:  To use structured diagnostic interviews to determine psychiatric comorbidity in 
adults with MUD. 
Hypothesis 1.1:  Psychiatric comorbidity is common in adults with primary MUD. 
Hypothesis 1.2:  Psychiatric disorders characterized by impulsivity are common in adult 
MUD. 
 
Objective 2:  To delineate impulsive comorbid disorders in MUD using a cluster analysis (CA) 
method. 
Hypothesis 2.1:  Given the heterogeneous nature of impulsivity, comorbid disorders in MUD 
that are characterized by impulsivity will group into 2 or more clusters using a CA. 
 
Objective 3: To explore the association of the identified clusters with demographic (age, 
gender) and clinical variables (i.e. illness severity, level of impulsivity).  
 
Research Setting 
Recruitment was done in the Western Cape Province of SA. Semi-structured interviews were 
conducted in a private office (by the incumbent, Mr Edrich Rall) - either at a treatment center, 
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rehabilitation organization, or at the Stellenbosch University (SU) / University of Cape Town (UCT) 
Medical Research Council’s Unit on Risk and Resilience in Mental Disorders (SU/UCT MRC). 
 
Ethical Considerations 
The research proposal was submitted for ethical approval at the Human Research Ethics Committee 
(HREC) at UCT.  Ethical approval for the study was received on 12 March 2018 (UCT HREC 
reference number: 074/2018) (Appendix 1). 
Participants who provided signed consent were included in the study.  Information on the 
study aims and procedures was available in Afrikaans and English.  All participants participated 
voluntarily and were informed that they may refuse or stop participation at any time without negative 
consequences. 
The information that was collected during the interview was treated as confidential and all 
participants’ data was stored in a file with a unique participant identification number (e.g. MA001).  All 
files were stored in a locked drawer in an office at the SU/UCT MRC and electronic data was stored 
on a password-protected computer. 
All participants that presented with psychiatric comorbidity or who requested treatment for MA 
use were referred to an appropriate treatment provider.  The interviewer provided a referral letter on 
request.  After the interview, all participants received a R75 grocery voucher for time dedicated to the 
study.   
 
Suggested Journal for Publication  
This section proposes the suggested journal for publication of the research manuscript (Chapter 2).  
The “Instructions to Authors” can be seen in the Appendices as “Appendix 2”.  
For this research project the researcher (Edrich Rall), together with his supervisors (Prof 
Christine Lochner, SU; Dr Henk Temmingh, UCT), selected the Journal of Substance Use (Online; 
ISSN: 1475-9942) for publication of this manuscript.  The Journal of Substance Use (Online) is an 
international peer-reviewed journal published in the United Kingdom by the Radcliffe Medical Press 
that aims to publish high-quality and original research and is accredited by the South African 
Department of Education. 
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CHAPTER TWO 
PUBLICATION-READY MANUSCRIPT 
CLUSTER ANALYSIS OF DISORDERS CHARACTERISED BY IMPULSIVITY IN PATIENTS WITH 
METHAMPHETAMINE USE DISORDER 
 
ABSTRACT 
Background 
Individuals with methamphetamine use disorder (MUD) frequently present with psychiatric 
comorbidities with impulsive features.  Little research has been conducted on comorbidity with 
impulsive features in MUD.  Therefore, this cross-sectional study aimed to delineate comorbid 
disorders with impulsivity in adult patients with a primary diagnosis of MUD.   
 
Methods 
Participants with lifetime MUD were included.  Well established measures screened for comorbid 
psychiatric disorders with impulsive features.  Illness severity was measured by the Yale Brown 
Obsessive-Compulsive Scale – adapted for drug use.  The UPPS-P Impulsive Behavior Scale was 
used to assess impulsivity levels.  A cluster analysis (CA) of lifetime comorbid disorders with 
impulsive features was performed. Demographic and clinical correlates of each identified cluster were 
identified. 
 
Results  
Sixty five (n = 65) adults with a primary diagnosis of MUD took part in the study.  They were 
predominantly female (44 females; 21 males), with ages ranging between 18 and 44 years (mean = 
30 years; SD = 6.53).  The CA rendered 4 groups.  Cases (n=12) in the “alcohol cluster” presented 
with AUD as their only impulsive disorder other than MUD.  Cases (n=19) in the “healthy cluster” had 
no comorbidity.  Cases (n=15) in the “antisocial cluster” all had comorbid antisocial personality 
disorder as well as polysubstance use disorders.  Cases (n=19) in the “borderline cluster” had 
borderline personality disorder and polysubstance use disorders.  Illness severity (Y-BOCS-du: 
p=0.03) and impulsivity levels (UPPS-P: p=0.01) differed significantly between the clusters.  The 
“alcohol cluster” had the highest illness severity and the “antisocial cluster reported the highest levels 
of impulsivity.   
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Conclusion  
The findings of this contribute to the paucity data on impulsivity in MUD and may have implications for 
treatment.  Understanding how these conditions cluster in MUD, and remaining cognizant of the 
demographic and clinical correlates of each cluster in MUD, could potentially enable clinicians to 
identify patients who are at higher risk for engaging in risky behaviors rendering them more vulnerable 
to treatment non-adherence or relapse. 
 
Keywords:  Cluster analysis; Comorbidity; Impulsive comorbidity; Impulsivity; Methamphetamine use 
disorder; Substance use disorder 
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Introduction 
Methamphetamine (MA) is a highly addictive stimulant and MA use has become is a major problem 
across the globe and especially so in the Western Cape Province of South Africa in recent years 
(Akindipe et al., 2014; Dada, Burnhams, et al., 2017).  Methamphetamine use disorder (MUD) is 
characterized by a pattern of MA use that results in functional  impairment (APA, 2013), with 
significant psychiatric comorbidity ( e.g. (Akindipe et al., 2014; Harker et al., 2008; Kalechstein et al., 
2000; Lin et al., 2004; Salo et al., 2011) ranging from anxiety (Akindipe et al., 2014; Salo et al., 2011) 
and mood disorders (Kalechstein et al., 2000; Plüddemann et al., 2013; Yen & Chong, 2006) to 
neurological problems, such as attention deficit hyperactivity disorder (ADHD) (Obermeit et al., 2013). 
Methamphetamine use disorder has also been associated with problems with impulsivity 
(Brooks et al., 2017).  Although not a psychiatric diagnosis in itself, impulsivity is a key feature of 
many psychiatric conditions (APA, 2013; Moeller et al., 2001).  Impulsivity is frequently seen in 
personality disorders, such as antisocial- (ASPD) and borderline personality disorder (BPD) (Few, 
Lynam, & Miller, 2015; Kisa, Yildirim, & Göka, 2005; Robbins et al., 2012), and is a hallmark feature of 
the disruptive-, impulse control- and conduct disorders, and is also common in eating disorders, 
obsessive-compulsive and related disorders, and in SUDs (APA, 2013). 
 There is a paucity of research on MUD and comorbidity characterised by impulsivity.  It has 
however been established that MA users have higher impulsivity as compared to healthy controls 
(Hoffman et al., 2006; Mahoney et al., 2015).  Several studies have reported that disorders with 
impulsive features, such as ASPD, BPD, and other SUDs often co-occur with MUD (e.g. (Plüddemann 
et al., 2013; Salo et al., 2011).  A better understanding of the relationship between impulsivity and 
other characteristics of MA users may have important clinical significance. It is with this in mind that 
this study aimed to delineate psychiatric comorbidity with impulsive features in adult patients with a 
primary diagnosis of MUD.  
Firstly, structured diagnostic interviews were used to determine impulsive psychiatric 
comorbidity in individuals with MUD.  It was hypothesized that the sample would have high rates of 
psychiatric comorbidity and more specifically, that disorders characterised with impulsivity would be 
common among individuals with MUD.  Secondly, impulsive comorbid disorders in MUD were 
delineated using a CA method and it was hypothesized that comorbid disorders characterized by 
impulsivity will fall into 2 or more clusters.  Thirdly, the associations of the identified clusters with 
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demographic (age, gender and level of education) and clinical variables (i.e. illness severity) were 
assessed using one-way analysis of variance (ANOVA).   
 
Methods 
This project was a secondary analysis of data collected by the Stellenbosch University (SU) / 
University of Cape Town (UCT) Medical Research Council’s Unit on Risk and Resilience in Mental 
Disorders (SU/UCT MRC).  The data analyzed was sourced from an ongoing project at this Unit, 
named “Gambling Disorder and MUD: A neurocognitive, genetic and neuroimaging study”.  This 
project was launched in September 2015 and received ethical approval from the IRBs of SU 
(reference number N14/05/053) and UCT (reference number 770/2014), respectively. 
Adult males and females were recruited from the community through newspaper 
advertisements and from local treatment centers (inpatient and outpatient).  Only individuals with a 
history of or current MA use were recruited for this study.  Participants from treatment centers or other 
institutions were screened by a referral practitioner before referral to our study.  If all of the inclusion 
criteria were met, participants were scheduled for a semi-structured interview.  Inclusion criteria were: 
a primary diagnosis of MUD, aged between 18 and 65 years, and residing in the Western Cape 
Province of South Africa.  Individuals with a history of other mental illnesses or abuse of additional 
(i.e. non-MA) substances were allowed to participate in the study.  Individuals with a history of 
psychosis were excluded.  
The majority of participants were interviewed at the SU/UCT MRC.  Participants from inpatient 
treatment centers were seen at the respective facility and outpatient participants were either seen in 
an office at their treatment center or at the above-mentioned unit.  After the interview at the SU/UCT 
MRC (done by the incumbent under supervision of Prof Christine Lochner, a registered clinical 
psychologist and principle investigator (PI) (of the parent project) the data was entered and organized 
in an electronic database.  Data collection ended on 30 March 2018.   
Assistance with statistical analysis was obtained from a statistician from the Centre of 
Statistical Consultation at the Department of Statistics and Actuarial Sciences at SU.  A cluster 
analysis (Ward’s method) (CA) was used to identify homogeneous groups within the MUD dataset 
(Statistics Solutions, 2018).  A CA is an explanatory analysis that is used to identify structures in a 
dataset (Statistics Solutions, 2018).  In theory, CA divides cases that are similar (high within group-
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homogeneity) into groups, referred to as clusters (Clatworthy et al., 2005).  Here, group entities 
(cases) were clustered on the basis of their similarities (comorbid diagnoses).  This method is 
commonly used in psychiatry (Clatworthy et al., 2005) and deemed suitable to use with comorbidity 
(binary / categorical) data.  “Ward’s method” is a specific hierarchical clustering strategy that was 
used here to delineate disorders characterized by impulsivity in a sample of patients with a primary 
diagnosis of MUD. 
A CA can perform a number of useful functions to organise large quantities of data 
(Clatworthy et al., 2005).  Moreover, cluster analysis has the potential to make a major contribution to 
applied health psychology research through the identification of groups that might best benefit from 
interventions or further research (Clatworthy et al., 2005).  Identifying these high-risk groups may 
ultimately guide the development of interventions for appropriate targets (Clatworthy et al., 2005). 
 
Materials 
Screening of potential participants was done telephonically or via email with a screening 
questionnaire (Appendix 3) and all participants provided signed consent for participation.  The current 
version of the consent form can be seen in the appendices as “Appendix 4”.  After consent was 
provided, the interview commenced.  A questionnaire with questions on demographics (i.e. age, sex, 
population (ethnicity), language, level of education, and occupation) was completed during the 
interview.  
The Substance Use Disorder module of the Structured Clinical Interview for DSM-5 Disorders 
(SCID-5) was administered to diagnose MUD and other substance use disorders (sedatives, 
cannabis, stimulants, opioids, inhalants, phencyclidine, hallucinogens, and other). 
The Mini-international neuropsychiatric interview (MINI) (Sheehan et al., 1994) was used to 
assess diagnostic status of other comorbidities (Lejoyeux et al., 2002).  It assessed for depressive 
disorders (dysthymia, mania, and suicidality), anxiety disorders (panic disorder, agoraphobia, social 
anxiety disorder, general anxiety disorder, obsessive-compulsive disorder, and posttraumatic stress 
disorder), psychotic disorders and mood disorders with psychotic features, eating disorders (anorexia 
nervosa and bulimia nervosa), and ASPD.  
The Structured Clinical Interview for the Diagnosis of Personality Disorders (SCID-II) was 
used to assess for borderline personality disorder (BPD) (Pihl, 2007).  In addition to the SCID II, the 
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Structured Clinical Interview for the Diagnosis of Obsessive-Compulsive Spectrum Disorders (SCID-
OCSD) (du Toit et al., 2001) was administered to assess impulse control disorders (ICD’s), including 
kleptomania, pyromania, trichotillomania, and intermitted explosive disorder.  The SCID-OCSD also 
assessed for “behavioral addictions”, such as gambling disorder (GD).  
The UPPS-P Impulsive Behavior Scale (UPPS-P) (Lynam, et al., 2006) was used to assess 
impulsivity. The UPPS-P is a 59-item self-report inventory, designed to measure personality pathways 
of impulsive behavior (Erfan, 2010).  Participants responded to items on a four point Likert scale (1 - 
agree strongly, 2 - agree some, 3 – disagree some, 4 - disagree strongly) (Claes et al., 2015; Nathan 
Kline Institute, 2016), with higher scores suggesting increased rates of impulsivity.  The UPPS-P also 
provides a total score that indicates the level of impulsivity of the respondent.    
The Yale-Brown Obsessive-Compulsive Scale modified to reflect obsessions and 
compulsions related to drug use (Y-BOCS-du) (Friedman, Dar, & Shilony, 2000) was used to assess 
MA use severity.  Items 1 to 5 comprise the obsessionality subscale and reflect drug-related thoughts 
whereas items 6 to 10 comprise the compulsivity subscale and reflect drug-related behaviors.  The 
total score of the questionnaire is the sum of items 1 to 10 (range = 0 to 40).  The internal consistency 
of the Y-BOCS-du has been reported to be 0.70 (Cronbach Alpha) (Friedman et al., 2000). 
.A total of 16 disorders with impulsive features were included in the analysis, ranging from mood 
disorders, personality disorders, other SUDs, disruptive-, impulse control- and conduct disorders, and 
so called “behavioral addictions”, to eating disorders, neurodevelopmental disorders, motor disorders, 
and obsessive-compulsive and related disorders (APA, 2013).  Specifically, mood disorders such as 
bipolar disorder (BD) and some personality disorders, such as ASPD and BPD and other SUDs (other 
than MUD) were included.  The SUDs were alcohol use disorder (AUD), other stimulant use disorders 
(e.g. cocaine), cannabis, and sedative hypnotics and anxiolytics (such as methaqualone / mandrax).  
Of the disruptive-, impulse-control-, and conduct disorders, intermitted explosive disorder (IED), 
pyromania, kleptomania, oppositional defiant disorder (ODD) compulsive shopping and GD were 
included.  Impulsivity is furthermore regarded as an important feature in some eating disorders, 
resulting in the inclusion of bulimia nervosa and anorexia nervosa in the analysis.  Of the 
neurodevelopmental disorders attention deficit disorder (ADD) and attention deficit hyperactivity 
disorder (ADHD) were included; and the obsessive-compulsive and related disorders included here 
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were obsessive-compulsive disorder (OCD) and trichotillomania (hair-pulling disorder).  The accepted 
level of significance (alpha level and p-value) was < 0.05 for the appropriate statistical tests. 
 
Results 
Sixty five (n = 65) adults with a primary diagnosis of MUD took part in the study.  They were 
predominantly female (44 females; 21 males), with ages ranging between 18 and 44 years (mean = 
30 years; SD = 6.53).  The majority of participants were of mixed race ancestry (n = 60; 92%), and 
unemployed (n = 47; 72%).   
Of the 16 psychiatric disorders characterised by impulsivity that were investigated here, nine 
(9) featured in our sample.  These ranged from personality disorders, SUDs (other than MUD), eating 
disorders, and disruptive, impulse control- and conduct disorders, neurodevelopmental disorders and 
obsessive-compulsive and related disorders. 
 
Lifetime Impulsive Comorbidity  
The lifetime prevalence of comorbidities with impulsivity was firstly determined.  We found that 70% (n 
= 46) of cases with MUD met a lifetime diagnosis of any comorbid disorder characterised by 
impulsivity.  More than a third (n = 23; 35%) of the cohort was diagnosed with a personality disorder; 
i.e. ASPD (n = 14; 21%) or borderline personality disorder (BPD) (n = 9; 13%).  Substance use 
disorders were also high in this sample.  Almost two-thirds of cases (n = 41; 63%) met a comorbid 
diagnosis of at least one SUD, other than MUD.  Three comorbid SUDs were identified – alcohol use 
disorder (AUD), cannabis use disorder (CUD), and methaqualone / mandrax use disorder (MxUD).  Of 
these, AUD was diagnosed in nearly half (n = 31; 47%) of the participants.  Cannabis use disorder 
was diagnosed in almost a third of cases (n = 21; 32%) and MxUD in 24 (36%) of the participants. 
 Two participants had an eating disorder, i.e. anorexia nervosa and binge eating disorder, 
respectively.  Of the disruptive, impulse control- and conduct disorders, 5 (7%) participants had a 
positive diagnosis; one participant was diagnosed with comorbid intermitted explosive disorder (IED) 
and another with kleptomania.  Furthermore, three participants had a comorbid diagnosis of gambling 
disorder (GD) and four (6%) participants were diagnosed with attention deficit hyperactivity disorder 
(ADHD) and one with trichotillomania (hair-pulling disorder). 
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Cluster Analysis  
The 65 cases were included in the CA.  Using Ward’s CA method with Euclidean distances 
heuristically, cases were clustered in 4 groupings at a linkage distance of 6.63, as depicted in a 
dendrogram (tree-diagram) (Figure 1).  These comorbid disorders were ASPD, BPD, AUD, CUD and 
MxUD and were the only disorders identified at the given linkage distance (Figure 2).   
In terms of impulsive comorbidity, Cluster 1 (n = 12), labeled the “alcohol cluster”, had 
comorbid AUD only.  Referred to as the “healthy cluster”, cluster 2 cases (n = 19) reported no 
impulsive conditions other than MUD.  Cluster 3 (n = 15), the “antisocial cluster” were diagnosed with 
ASPD and polysubstance use disorders, and Cluster 4 (n = 19), the “borderline cluster”, had BPD and 
polysubstance use disorders, in addition to their primary MUD.   
 
Associated Features of the Identified Clusters   
Clusters did not differ from one another in terms of their demographic characteristics but notably, 
Cluster 1 cases (“alcohol cluster”) were all female and cases in Cluster 3 (“antisocial cluster”) were 
mostly male (60%).  Eighty percent of the Cluster 3 cases had ASPD, 6% BPD, 46% AUD, 26% CUD, 
and 80% had MxUD.  Ten percent of the cases in the “borderline cluster” (Cluster 4) had ASPD, 42% 
had BPD, 63% had AUD, 89% CUD, and 63% of MxUD. 
There was a statistically significant difference in impulsivity level, as measured with the 
UPPS-P, between the clusters (F(3, 61) = 3.54; m = 146.01; sd = 24.23; p = 0.01) (Figure 3).  
Impulsivity in the “healthy cluster” was not significantly different from the “alcohol cluster”, but was 
significantly lower than that of the “antisocial cluster” (p = 0.01) and “borderline cluster” (p = 0.04).  
Post hoc LSD-tests revealed that the “antisocial cluster” scored the highest in impulsivity, being 
significantly higher than the “alcohol cluster” and the “healthy cluster”, but not in relation to the 
“borderline cluster”.  The “borderline cluster” reported the second highest in impulsivity, only being 
significantly different in this regard to the “healthy cluster”. 
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Table 1:  Total UPPS-P scores of each cluster. 
UPPS-P 
Cluster 
UPPS-P total score 
 
 
Mean Standard deviation 
“Alcohol cluster” 136.00 24.23 
“Healthy cluster” 136.94 24.10 
“Antisocial cluster” 157.93 17.85 
“Borderline cluster” 152.00 23.93 
 
For the Y-BOCS-du significant differences were reported between the clusters (F(3, 61) = 
2.97; m = 23.89; sd = 10.40; p = 0.03) (Figure 4). Post hoc LSD-test comparisons on the Y-BOCS-du 
determined that cluster 1 (p=0.01) and 4 (p=0.01) were significantly more severely ill compared to 
cluster 2, and no differences in illness severity were reported between cluster 3 and the other 
clusters. 
 
Table 2:  Differences in illness severity between clusters as measured with the Y-BOCS-du. 
Measure Cluster 
Total 
score 
(mean) 
Std. 
deviation 
p-value 
Y-BOCS-du 
Cluster 1: Alcohol cluster 27.50 8.78 
0.03 
Cluster 2: Healthy cluster 18.68 9.82 
Cluster 3: Antisocial cluster 23.40 11.30 
Cluster 4: Borderline cluster 27.21 9.62 
 
Discussion  
There has been little systematic investigation of the nature and implications of comorbidity of 
disorders characterized by impulsive features in MUD.  Understanding how such conditions cluster in 
MUD, with their associated demographic and clinical features, may potentially guide selection of 
treatment targets, selecting appropriate interventions, harm reduction, and prevent relapse in MUD.   
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The main findings of this investigation were 1) that disorders characterised by impulsivity 
were common among individuals with MUD; 2) that impulsive comorbid disorders in MUD clustered 
into 4 clusters, which were subsequently labeled as the ”alcohol cluster”, “healthy cluster”, 
“antisocial”- and “borderline cluster”; and 3) that the antisocial MUD cluster was mostly male and had 
the highest impulsivity scores, and the ”alcohol cluster” was mostly female and had the highest illness 
severity scores, in comparison to the other clusters.  
This study showed that psychiatric comorbidity was common in this population (e.g. Akindipe 
et al., 2014; Dada, Burnhams, et al., 2017; Harker et al., 2008; Morisano et al., 2014; Plüddemann et 
al., 2013).  More specifically, 70% of our sample had a lifetime diagnosis of a psychiatric disorder with 
impulsive features.  This was higher compared to reports from other local and international work on 
MUD and psychiatric comorbidity (such as Akindipe et al., 2014; Glasner-Edwards et al., 2010) and 
might be attributed to recruitment of most of the study sample from an inpatient psychiatric institution 
where they were following a rehabilitation program to address MUD and related problems. 
As noted earlier, impulsivity and substance use often constitute elements of a vicious cycle; 
i.e. impulsivity may increase the likelihood of using stimulants such as methamphetamine, which in 
turn may increase impulsivity, again leading to potentially hazardous drug use and other risky 
behaviors. It thus makes sense that comorbid psychiatric disorders characterized by impulsivity in 
MUD may increase the risk of abusing other substances (Conway, Compton, Stinson, & Grant, 2006) 
and it has been suggested that the most prevalent comorbidities in psychiatric populations (Weich & 
Pienaar, 2009) and in MUD (Salo et al., 2011) are other SUD’s.  The CA conducted here identified 
four clusters: an “alcohol cluster”, a “healthy cluster”, an “antisocial cluster”, and a “borderline cluster”.  
Cases in all clusters, except the “healthy cluster” abused one or more substances other than MA.  In 
particular, cases in clusters 3 and 4 were also marked with polysubstance (in addition to MA) use 
disorders.   
In terms of demographic correlates, it is notable that the “alcohol cluster” comprised of 
females only.  It has been suggested that women may be less likely to abuse illicit substances (Dove 
& Joseph, 2007; Hecksher & Hesse, 2009), but are more likely to have problems with alcohol (Dove & 
Joseph, 2007; Vythilingum, Roos, Faure, Geerts, & Stein, 2012).  Alcohol abuse may however have 
rendered this group more vulnerable to MA use.  This group also presented with highest illness 
severity scores, suggesting that the combination of MA use, alcohol use disorder and female gender 
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present a particularly vulnerable group.  This was partly consistent with other work suggesting that 
women with alcohol-related problems had increased illness severity (McCutcheon et al., 2011). The 
predominance of males in the antisocial MUD cluster is consistent with other work suggesting a 
strong link between ASPD and male gender (Chun et al., 2017).  Cases in this cluster presented with 
a combination of ASPD, male gender and MUD, and had the highest impulsivity scores compared to 
the others, suggesting that this is a particularly high risk group of individuals.  The antisocial MUD 
cluster cases had increased rates of ASPD and polysubstance use disorders.  Individuals with ASPD 
often present with an increased number of SUDs (Ogloff, Talevski, Lemphers, Wood, & Simmons, 
2015).  Similar, the current study found that MUD with comorbid ASPD was associated with co-
occurring SUDs, as 80% of cases this cluster met the diagnosis of MxUD, 46% AUD, and 26% CUD. 
The associated features of the “borderline cluster” were expected: these cases were 
predominantly female (63%) and reported the highest rates of polysubstance use disorders in 
comparison to the other clusters.  The link between BPD and female gender has been repeatedly 
reported (Chun et al., 2017).  In addition, BPD has also often been linked to polysubstance use (Trull, 
Sher, Minks-Brown, Durbin, and Burr, 2000). The majority of cases in the current study (89%) met a 
comorbid diagnosis CUD and had high rates of AUD (63%) and CUD (63%).   
The correlation of the two clusters characterised by personality disorders (i.e. the antisocial- 
and borderline clusters) with polysubstance use disorders are consistent with existing literature that 
have suggested a link between personality pathology and substance abuse.  This might be attributed 
to common underlying features, such as personality characteristics such as impulsivity (Dellazizzo et 
al., 2018), genetic, behavioural and cognitive factors (Rzhetsky, Wajngurt, Park, & Zheng, 2007; 
Smith, Mattick, Jamadar, & Iredale, 2014), or shared risk markers for externalizing behaviors of these 
conditions (Brook, Zhang, Rubenstone, Primack, & Brook, 2016; Trull et al., 2000).   
Impulsivity has frequently been associated with SUDs (Taylor et al., 2016) and studies have 
suggested high levels of impulsivity in these populations (e.g. Hoffman et al., 2006; Mahoney et al., 
2015; Moeller et al., 2001).  Increased substance use comorbidity was associated with higher levels 
of impulsivity (Smith et al., 2014) and the findings here indicated that additional impulsive comorbidity 
was also linked with greater impulsivity in general.  Smith et al. (2014) indicated that having a smaller 
number of SUDs were linked to lower impulsivity levels.  This finds support in our finding that cases in 
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the “alcohol”- and “healthy” clusters scored lower on the UPPS-P in comparison to the “antisocial”- 
and “borderline” cluster.  
The results may potentially guide understanding of the ways in which MUD present, of the risk 
factors to consider during care, and may ultimately assist in improving outcomes in these patients.  
Cognizance of the demographic and clinical correlates of impulsivity in MUD may aid practitioners in 
providing appropriate treatment to selected targets.  For example, it may be suggested that MUD 
cases that fit the cluster 3 profile (i.e. male, with comorbid ASPD and polysubstance use) may benefit 
from treatments that include impulse and aggression control components.  Similarly, illness severity of 
patients that fit the profile of the borderline MUD cluster (likely female, with comorbid BPD) would 
likely be very high, potentially necessitating additional support on multiple levels, including assistance 
with personality- or interpersonal difficulties. 
There are a few study limitations deserving mention. First, the sample was mostly female 
which is atypical as most other MUD studies suggest an association between MUD and male gender 
(Akindipe et al., 2014). The female preponderance of the current investigation resulted from the initial 
recruitment drives at clinics with female patients only.  However, this makes the finding of a 
connection between the antisocial MUD cluster and male gender even more noticeable. Second, most 
of the sample was recruited from drug treatment centers, psychiatric institutions, and other health 
care practitioners, which may limit the extent of generalisability of our findings to the population of MA 
dependent individuals within the community.  Thirdly, the small sample size may also be a limitation.  
Finally, this project was limited by the overarching project’s data which did not include all conditions 
with impulsive features (e.g. histrionic personality disorder and narcissistic personality disorder were 
not assessed and the data thus not available).Future studies on impulsive comorbidity in patients with 
MUD may benefit from a more gender-balanced and a larger sample, recruited from several different 
contexts (clinic and community).  Inclusion of all conditions characterized by impulsivity should be 
emphasized to provide a comprehensive overview of impulsive comorbidity in MUD.  
 
Conclusion  
In conclusion, MA use has increased globally in recent years, reaching epidemic proportions in South 
Africa, particularly in the Western Cape Province.  This study responded to pleas that highlighted the 
need for further research on MA use locally - as a matter of social development, safety and public 
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health.  The findings contribute to the paucity of research on MUD and comorbid disorders 
characterized by impulsivity. Understanding how these conditions cluster in MUD, and remaining 
cognizant of the demographic and clinical correlates of each cluster in MUD, could potentially enable 
clinicians to identify patients who are at higher risk for engaging in risky behaviors rendering them 
more vulnerable to treatment non-adherence or relapse.  Such an understanding may potentially 
guide treatment strategies, and ultimately improve outcome in these patients. 
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Author Guidelines for the Journal of Substance Use 
Extracted from: https://www.tandfonline.com/action/authorSubmission?journalCode=ijsu20&page=instructions 
Instructions for authors 
Thank you for choosing to submit your paper to us. These instructions will ensure we have everything 
required so your paper can move through peer review, production and publication smoothly. Please 
take the time to read and follow them as closely as possible, as doing so will ensure your paper 
matches the journal's requirements. For general guidance on the publication process at Taylor & 
Francis please visit our Author Services website.  
ScolarOne Manuscripts 
This journal uses ScholarOne Manuscripts (previously Manuscript Central) to peer review manuscript 
submissions. Please read the guide for ScholarOne authors before making a submission. Complete 
guidelines for preparing and submitting your manuscript to this journal are provided below.  
About the journal 
Journal of Substance Use is an international, peer-reviewed journal publishing high-quality, original 
research. Please see the journal’s Aims & Scope for information about its focus and peer-review 
policy. 
Please note that the journal only publishes manuscripts in English. 
Peer review 
Taylor & Francis is committed to peer-review integrity and upholding the highest standards of review. 
Once your paper has been assessed for suitability by the editor, it will then be single blind peer-
reviewed by expert referees.  Find out more about what to expect during peer review and read our 
guidance on publishing ethics. 
Preparing your paper 
All authors submitting to medicine, biomedicine, health sciences, allied and public health journals 
should conform to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, 
prepared by the International Committee of Medical Journal Editors (ICMJE). 
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Length of Manuscripts 
Manuscripts should be in English and up to 3000 words in length. Articles of any length will be 
considered. Please discuss longer articles with the Editor before submission. 
 
Structure 
Your paper should be compiled in the following order:  title page; abstract; keywords; main text 
introduction, materials and methods, results, discussion; acknowledgments; declaration of interest 
statement; references; appendices (as appropriate); table(s) with caption(s) (on individual pages); 
figures; figure captions (as a list). 
 
Formatting and templates 
Papers may be submitted in any standard file format, including Word and LaTeX. Figures should be 
saved separately from the text. The main document should be double-spaced, with one-inch margins 
on all sides, and all pages should be numbered consecutively. Text should appear in 12-point Times 
New Roman or other common 12-point font.  
 
Style guidelines 
Submissions to Journal of Substance Use should follow the style guidelines described in APA 
Publication Manual (6th ed.). Merriam-Webster’s Collegiate Dictionary (11th ed.) should be consulted 
for spelling. 
 
References 
Please use this reference guide when preparing your paper. 
 
Checklist: what to include 
 
Author details. All authors of a manuscript should include their full name and affiliation on the cover 
page of the manuscript. Where appropriate, please also include ORCiDsand social media handles 
(Facebook, Twitter or LinkedIn). One author will need to be identified as the corresponding author, 
with their email address normally displayed in the published article. Authors’ affiliations are the 
affiliations where the research was conducted. If any of the named co-authors moves affiliation during 
the peer-review process, the new affiliation can be given as a footnote. Please note that authorship 
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may not be changed after acceptance. Also, no changes to affiliation can be made after your paper is 
accepted.  
 
Structured abstract.  This summary of your article is normally no longer than 200 words. You should 
divide your structured abstract into the following sections: (a) Background or Objective, (b) Methods, 
(c) Results, (d) Conclusions. Each section of the abstract should feature an appropriate heading. 
Read tips on writing your abstract.  
 
Keywords. Keywords are the terms that are most important to the article and should be terms 
readers may use to search.  Authors should provide 3 to 5 keywords. Please read our page 
about making your article more discoverable for recommendations on title choice and search engine 
optimization. 
 
Funding details. Please supply all details required by your funding and grant-awarding bodies as 
follows: 
For single agency grants 
This work was supported by the <Funding Agency> under Grant <number xxxx>. 
 
For multiple agency grants 
This work was supported by the <Funding Agency #1> under Grant <number xxxx>; <Funding 
Agency #2> under Grant <number xxxx>; and <Funding Agency #3> under Grant <number xxxx>. 
 
Disclosure statement. With a disclosure statement you acknowledge any financial 
 interest or benefit that has arisen from the direct applications of your research. Further guidance, 
please see our page on what is a conflict of interest and how to disclose it. 
 
Supplemental online material. Supplemental material can be a video, dataset, fileset, sound file, or 
anything else which supports (and is pertinent to) your paper. Supplemental material must be 
submitted for review upon paper submission.  Additional text sections are normally not considered 
supplemental material.  We publish supplemental material online via Figshare. 
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Figures. Figures should be high quality (600 dpi for black & white art and 300 dpi for color). Figures 
should be saved as TIFF, PostScript or EPS files.  Figures embedded in your text may not be able to 
be used in final production.
Tables. Please supply editable table files.  We recommend including simple tables at the end of your 
manuscript, or submitting a separate file with tables. 
Equations. If you are submitting your manuscript as a Word document, please ensure that equations 
are editable. Please see our page on mathematical symbols and equations for more information. 
Author agreement / Use of third-party material
Authors are responsible for obtaining permission to reproduce copyrighted material from other 
sources and are required to sign an agreement for the transfer of copyright to the publisher. As an 
author you are required to secure permission if you want to reproduce any figure, table or extract text 
from any other source. This applies to direct reproduction as well as "derivative reproduction" (for 
which you have created a new figure or table which derives substantially from a copyrighted source). 
Please see our page on requesting permission to reproduce work(s) under copyright for more 
guidance. Authors are required to sign an agreement for the transfer of copyright to the publisher. All 
accepted manuscripts, artwork, and photographs become property of the publisher. 
Guidelines for medicine and health publications 
Disclosure of interest
Please include your disclosure statement under the subheading “Disclosure of interest.” If you have 
no interests to declare, please state this (suggested wording: The authors report no conflict of
interest). For all NIH/Wellcome-funded papers, the grant number(s) must be included in the 
declaration of interest statement.  
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Clinical Trials Registry 
In order to be published in a Taylor & Francis journal, all clinical trials must have been registered in a 
public repository at the beginning of the research process (prior to patient enrollment). Trial 
registration numbers should be included in the abstract, with full details in the methods section. The 
registry should be publicly accessible (at no charge), open to all prospective registrants, and 
managed by a not-for-profit organization. For a list of registries that meet these requirements, please 
visit the WHO International Clinical Trials Registry Platform (ICTRP). The registration of all clinical 
trials facilitates the sharing of information among clinicians, researchers, and patients, enhances 
public confidence in research, and is in accordance with the ICMJE guidelines. 
 
Complying with ethics of experimentation 
Please ensure that all research reported in submitted papers has been conducted in an ethical and 
responsible manner, and is in full compliance with all relevant codes of experimentation and 
legislation. All papers which report in vivo experiments or clinical trials on humans or animals must 
include a written statement in the Methods section. This should explain that all work was conducted 
with the formal approval of the local human subject or animal care committees (institutional and 
national), and that clinical trials have been registered as legislation requires. Authors who do not have 
formal ethics review committees should include a statement that their study follows the principles of 
the Declaration of Helsinki. 
 
Consent. All authors are required to follow the ICMJE requirements on privacy and informed consent 
from patients and study participants. Please confirm that any patient, service user, or participant (or 
that person’s parent or legal guardian) in any research, experiment, or clinical trial described in your 
paper has given written consent to the inclusion of material pertaining to themselves, that they 
acknowledge that they cannot be identified via the paper; and that you have fully anonymized them. 
Where someone is deceased, please ensure you have written consent from the family or estate. 
Authors may use this Patient Consent Form, which should be completed, saved, and sent to the 
journal if requested.  
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Health and safety . Please confirm that all mandatory laboratory health and safety procedures have 
been complied with in the course of conducting any experimental work reported in your paper. Please 
ensure your paper contains all appropriate warnings on any hazards that may be involved in carrying 
out the experiments or procedures you have described, or that may be involved in instructions, 
materials, or formulae. 
 Please include all relevant safety precautions; and cite any accepted standard or code of 
practice. Authors working in animal science may find it useful to consult the International Association 
of Veterinary Editors’ Consensus Author Guidelines on Animal Ethics and Welfareand Guidelines for 
the Treatment of Animals in Behavioral Research and Teaching. When a product has not yet been 
approved by an appropriate regulatory body for the use described in your paper, please specify this, 
or that the product is still investigational. 
 
Submitting your paper 
Journal of Substance Use uses ScholarOne Manuscripts to manage the peer-review process. If you 
have not submitted a paper to this journal before, you will need to create an account in ScholarOne 
Manuscripts. Please read the guidelines above and then submit your paper in the relevant Author 
Center, where you will find user guides and a helpdesk. 
 If you are submitting in LaTeX, please convert the files to PDF beforehand (you will also need to 
upload your LaTeX source files with the PDF). Your manuscript must be accompanied by a statement 
that it has not been published elsewhere and that it has not been submitted simultaneously for 
publication elsewhere. 
We recommend that if your manuscript is accepted for publication, you keep a copy of your 
accepted manuscript. For possible uses of your accepted manuscript, please see our page on sharing 
your work. 
 
Data sharing policy 
This journal applies the Taylor & Francis Basic Data Sharing Policy. Authors are encouraged to share 
or make open the data supporting the results or analyses presented in their paper where this does not 
violate the protection of human subjects or other valid privacy or security concerns. 
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Authors are encouraged to deposit the dataset(s) in a recognized data repository that can mint a 
persistent digital identifier, preferably a digital object identifier (DOI) and recognizes a long-term 
preservation plan. If you are uncertain about where to deposit your data, please see this 
information regarding repositories.  
Authors are further encouraged to cite any data sets referenced in the article and provide 
a Data Availability Statement. 
At the point of submission, you will be asked if there is a data set associated with the 
paper.  If you reply yes, you will be asked to provide the DOI, pre-registered DOI, hyperlink, or other 
persistent identifier associated with the data set(s). If you have selected to provide a pre-registered 
DOI, please be prepared to share the reviewer URL associated with your data deposit, upon request 
by reviewers. 
Where one or multiple data sets are associated with a manuscript, these are not formally peer 
reviewed as a part of the journal submission process. It is the author’s responsibility to ensure the 
soundness of data. Any errors in the data rest solely with the producers of the data set(s). 
 
CrossRef Similarity Check 
Please note that Journal of Substance Use uses CrossRef Similarity Check™ (Powered by 
iThenticate) to screen papers for unoriginal material. By submitting your paper to the journal you are 
agreeing to originality checks during the peer-review and production processes. 
 
Color charges 
Color art will be reproduced in color in the online publication at no additional cost to the author. Color 
illustrations will also be considered for print publication; however, the author will be required to bear 
the full cost involved in color art reproduction. Please note that color reprints can only be ordered if 
print reproduction costs are paid. Print Rates:  $400 per figure for the first four figures; $75 per figure 
for five or more figures. 
 
Complying with funding agencies 
We will deposit all National Institutes of Health or Wellcome Trust-funded papers into PubMedCentral 
on behalf of authors, meeting the requirements of their respective open access (OA) policies. If this 
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applies to you, please ensure that you have included the appropriate funding bodies in your 
submission’s funding details section. You can check various funders’ OA policy mandates here and 
find out more about sharing your work here. 
Open access
This journal gives authors the option to publish open access via our Open Select publishing program, 
making it free to access online immediately on publication. Many funders mandate publishing your 
research open access; you can check open access funder policies and mandates here. 
Taylor & Francis Open Select gives you, your institution or funder the option of paying an article 
publishing charge (APC) to make an article open access. Please contact openaccess@tandf.co.uk if 
you would like to find out more, or go to our Author Services website. 
For more information on license options, embargo periods and APCs for this journal please 
go here. 
Proofs
Page proofs are sent to the corresponding author using Taylor & Francis’ Central Article Tracking
System (CATS). They should be carefully checked and returned within 48 hours. 
Reprints
Authors for whom we receive a valid e-mail address will be provided an opportunity to purchase 
reprints of individual articles, or copies of the complete print issue. These authors will also be given 
complimentary access to their final article on Taylor & Francis Online. 
For enquiries about reprints, please contact the Taylor & Francis Author Services team 
at reprints@tandf.co.uk. To order a copy of the issue containing your article, please contact our 
Customer Services team at Customer.Service@taylorandfrancis.com. 
My Authored Works
On publication, you will be able to view, download and check your article’s metrics (downloads, 
citations and Altmetric data) via My Authored Works on Taylor & Francis Online. We are committed to 
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promoting and increasing the visibility of your article. Here are some tips and ideas on how you can 
work with us to promote your research. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
51 
 
APPENDIX 3 
Recruitment Screening Questionnaire 
 
 
Date pt. called/emailed:            
Date pt. was called back/emailed:         
Recruited via:            
Name & Surname:           
Cell:              
Work:             
Home:             
Email:            
 
 
 
 
Notes:             
            
            
            
            
            
            
             
 
 
Suggested date of assessment:          
Location of assessment:           
Date of assessment confirmed by pt.?:        
 
 
 MUD   
1 MA primary drug of use?  yes no 
2 History of other drug use yes no 
3 History of psychopathology yes no 
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APPENDIX 4 
Participant Consent Form 
PARTICIPANT INFORMATION AND INFORMED CONSENT FORM  
(PATIENTS) 
 
TITLE OF RESEARCH PROJECT: Gambling disorder and methamphetamine use disorder: A 
neurocognitive, genetic and neuroimaging study 
 
REFERENCE NUMBERS:   SU HREC: N14/05/053     
     UCT HREC: 770/2014  
PRINCIPAL INVESTIGATORS:  SU: Prof Christine Lochner 
     UCT: Prof Dan Stein  
 
ADDRESS: MRC Unit on Risk and Resilience in Mental Disorders, Department of Psychiatry, Faculty 
of Medicine and Health Sciences, Stellenbosch University 
 
CONTACT NUMBERS: Lochner: 021 – 938 9179; Stein: 021 – 404 2174 
 
We would like to invite you to participate in a research study that involves genetic analysis and 
possible long-term storage of blood or tissue specimens.  Please take some time to read the 
information presented here which will explain the details of this project.  Please ask the study staff any 
questions about any part of this project that you do not fully understand.  It is very important that you 
are fully satisfied that you clearly understand what this research entails and how you could be 
involved.  Also, your participation is entirely voluntary and you are free to decline to participate.  If 
you say no, this will not affect you negatively in any way whatsoever.  You are also free to withdraw 
from the study at any point, even if you do agree to take part initially.  
 
This research study has been approved by the Health Research Ethics Committee at Stellenbosch 
University and the Human Research Ethics Committee at the University of Cape Town and it will 
be conducted according to international and locally accepted ethical guidelines for research, namely 
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the Declaration of Helsinki, and the SA Department of Health’s 2004 Guidelines: Ethics in Health
Research: Principles, Structures and Processes.
What is genetic research? 
Genetic material, also called DNA, is usually obtained from a small blood sample.  Occasionally 
genetic material is obtained from other sources such as saliva.  Genes are found in every cell in the 
human body.  Our genes determine what we look like and sometimes our susceptibility to certain 
kinds of diseases.  Worldwide, researchers in the field of genetics are continuously discovering new 
information.  This information may be of great benefit to both future generations and people today, 
who suffer from particular diseases or conditions. 
What does this particular research study involve? 
This study is part of a research project we are conducting to learn more about gambling disorder and 
methamphetamine use disorder.   
Doctors and scientists at the MRC Unit on Risk and Resilience in Mental Disorders, University of 
Stellenbosch, and the Department of Psychiatry, University of Cape Town, are collaborating with 
researchers from other research institutions worldwide to investigate the structure and functioning of 
selected brain areas in 40 individuals with gambling disorder and 40 individuals with 
methamphetamine use disorder.  This study also aims to identify the genes that may increase the risk 
for the development of these conditions.  Information from patients will be compared with 40 age- and 
gender-matched healthy controls. 
This is not a treatment study.  Information is being collected for research purposes only. 
Why have you been invited to participate? 
You have been invited to participate because you have indicated (either to your doctor, or to the 
National Responsible Gambling Programme's telephone counselling line which is affiliated with UCT's 
Addiction division) that you excessively gamble or use methamphetamine (“tik”) to the extent that it
affects your functioning.   
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Gambling disorder (GD) or pathological gambling can be defined as the inability to resist the urge to 
gamble despite severely negative personal or social consequences.  Similarly, methamphetamine use 
disorder (MUD) refers to the inability to resist taking the drug, and is often associated with repeated 
unsuccessful attempts to cut down, resulting in a failure to fulfill major obligations at work, school or 
home. 
 
What procedures will be involved in this research? 
If you decide to participate, we will ask you to attend 2-4 sessions, each with a different study focus.   
 
The first session will comprise an interview with a researcher and the drawing of bloods.  These 
procedures will last approximately 3-4 hours (with a break in-between, if need be). Depending on the 
preferences of your treatment centre, this session may be broken up into two sessions and the 
drawing of bloods and completion of questionnaires may be conducted in a group setting. The clinical 
interview will, amongst other things, include a number of questions related to gambling or 
methamphetamine use and your prior psychiatric history.  Approximately 20 ml (4 teaspoons) of blood 
will be drawn from your arm.  We may need to contact you again to get another blood sample should 
we fail to get a DNA sample (the genetic material) from your blood. The blood sample you give may 
be used to create a cell line. A cell line is living tissue that can be used to make more of your DNA at 
any time in the future.   Genetic material previously found to be associated with gambling disorder 
which may also play a role in brain activity, will also be investigated. This process will take place at 
the Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, at 
the University of Stellenbosch.  Should you not wish to provide us with a blood sample, you may 
provide us with a saliva sample instead.   
 
The second session will involve 2 hours of brain scanning followed by neuropsychological testing (i.e. 
computer based tasks to test abilities such as decision making) of approximately 1.5 hours’ duration. 
This session may also be broken up into two sessions, depending on your or your treatment centre’s 
preference, as well as transport availability. MRI (brain scanning) makes use of magnetic fields and 
radio waves to examine internal structures of the body. The procedure is non-invasive and completely 
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harmless. No ionising radiation (such as X-rays) or radio-active material are used during the study. 
MRI is particularly useful for imaging soft tissue such as the brain. It is capable of measuring certain 
characteristics of brain function. The procedure requires that you lie on your back with your head in a 
“tunnel” which is very similar to a CAT scan machine. The tunnel is open on both sides and is well lit 
and ventilated. You will at all times be in intercom contact with the radiographer, who will also be able 
to see you at all times. The examination will take about 90 minutes (with breaks if needed) and will be 
accompanied by a series of loud knocking sounds. There are no moving parts within the scanner, and 
the knocking sounds occur due to vibration of the machine in the magnetic fields. In some instances, 
the intravenous administration of contrast agent is also necessary, but you will be notified in advance 
about this.  Finally, it is important that you do not move at any stage during the examination as this 
makes the images blurry.  
 
The initial screening and assessment of GD or MUD patients as well as the drawing of bloods will 
take place either at the National Responsible Gambling Programme (NRGP) offices in Kenilworth, at 
the Faculty of Medicine and Health Sciences at the Tygerberg Campus of Stellenbosch University, or 
at the rehabilitation centre where you are currently being treated, depending on your preference for 
either location. The brain imaging will proceed at the recently established scanning centre at Groote 
Schuur Hospital (UCT). The computer-based tasks will proceed at the Faculty of Medicine and Health 
Sciences at the Tygerberg Campus of Stellenbosch University. You will receive grocery vouchers for 
participation and refreshments will be provided if requested. Where necessary, transport will also be 
provided. 
 
We may contact you later for further information, or request you to complete another interview at a 
later date, in order to obtain follow-up information that may be of use in our genetic analyses.  This 
may involve an assessment similar to the current assessment, including a series of interviews and/or 
another blood sample.  Your current participation is in no way binding to your future participation. 
 
Are there any risks involved in participation? 
There are no more than minimal medical or psychological risks associated with this study.  If you feel 
fatigued, uncomfortable, or in any way upset during any part of the session(s), you may ask to stop for 
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a rest break or have the interview or scanning discontinued.  The research interview does not take the 
place of a full psychiatric evaluation.  You may experience some emotional discomfort when 
answering some questions.  If any particular question makes you feel uncomfortable, you may 
discuss its importance with the specially trained interviewer.  You may choose not to answer any 
question should you feel uncomfortable. 
 
You may feel some pain associated with having blood drawn from a vein.  You may experience 
discomfort, bruising and/or other bleeding at the site where the needle is inserted.  Occasionally, 
some people experience fleeting dizziness or feel faint when their blood is drawn.  Some insurance 
companies may mistakenly assume that your participation in this study is an indication that you are at 
higher risk of a genetic disease, and this could hurt your access to health or other insurance.  We will 
not share any information about you, or your family, with an insurance company.  It is the opinion of 
the investigators that participation in this study does not constitute genetic testing.  Therefore, 
participation in this study should not be reported as genetic testing.   
 
You may feel some discomfort or fatigue associated with being in the brain scanner or while 
undergoing neuropsychological testing.   
 
Are there any benefits to your taking part in this study? Will the results of your participation be 
discussed with you? 
This study will hopefully provide useful data about the nature of problem gambling in South Africa, 
potentially filling gaps in the current body of knowledge regarding gambling.  Individuals who might 
develop one of these conditions in the future, their family members, and future generations may 
benefit from the project if we can locate the genes and brain structures or functions that may have led 
to these symptoms.  That knowledge may then be used for prevention or treatment planning and 
policy purposes 
 
Individuals who choose not to partake in this study are free to do so at no consequence and will be 
referred for treatment, if requested.  
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How long will your blood/DNA sample be stored and where will it be stored? 
Samples will be safely stored at -80 degrees Celsius at the Division of Molecular Biology and Human 
Genetics, Faculty of Medicine and Health Sciences, at the University of Stellenbosch, and de-
identified (identified by a code number), and access will be limited to authorised scientific 
investigators.  We also collaborate with researchers abroad; this means we may in future share DNA 
samples and anonymous (clinical or imaging) information with these sites to study your condition.   
Your DNA will be maintained permanently, unless you request to have it removed. If at any time in the 
future you wish to have your DNA or clinical data removed from the storage site, you may do so by 
contacting the researchers conducting this study.
Will your clinical and genetics information be used for other research? 
You can choose to share your clinical and DNA information with other scientists through a central 
database. In other words, the data that have been collected may be used for future investigations. 
Other researchers would be able to learn from your data and would be able to conduct studies that 
include DNA from many countries.  This can lead to larger and better studies related to gambling 
disorder, methamphetamine use disorder and other health conditions.   
An “online database” is a database that is created from the central database.  Researchers all over 
the world have access to this database (this is called “data sharing”).  The DNA stored in this online
database will be used for research into general medical conditions OR psychiatric illnesses. If South 
African researchers wish to use your stored blood/DNA for additional research in this field, they will be 
required to apply for permission to do so from the Health Research Ethics Committee at Stellenbosch 
University and the Human Research Ethics Committee at the University of Cape Town.  If researchers 
from abroad wish to use your DNA information that has been stored on the online database, they will 
be required to apply for permission to do so from the National Institute of Health in the United States 
of America. If you wish to withdraw your data or your sample in the future, this is possible. However, 
please note that by the time we withdraw your data or your sample, it may already have been shared 
with other researchers. The United States National Institute for Mental Health (NIMH) Repository 
would, however, then instruct researchers to destroy your data and your sample if requested. 
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Will your brain imaging data be shared with other researchers?  
In the same way as above, you can also choose to share your brain imaging data with researchers 
from other research institutions worldwide, to investigate, the structure and functioning of selected 
brain areas (anonymously). 
 
How will your confidentiality be protected? 
If you consent to participate in this study, your identity will be kept confidential.  Your answers will not 
be shared with other family members or anyone else except for staff members involved in this study.  
All research information and laboratory samples obtained from you will be safely stored and identified 
by code number. This means that no identifying information will be shared. Access will be limited to 
authorised scientific investigators.  Any publications resulting from this study will not identify you by 
name.   
 
Because some of your DNA/cells are going to be stored in the United States, there is a very small 
chance the United States government might forcibly gain access to it using one of their laws called 
“The Patriot Act”.  This Act is used when the United States government judges that access to DNA is 
important for security purposes. 
 
Will you or the researchers benefit financially from this research? 
You will not be paid to take part in this study although your travel expenses will be reimbursed. In 
addition to this, you will have the opportunity of winning some money in a monetary reward task. The 
exact amount you will receive is dependent on your performance on the task. 
 
Is there anything else that you should know or do? 
You can contact the principal investigator at Stellenbosch University, Christine Lochner, on 021 – 938 
9179 or CL2@sun.ac.za, or the principal investigator at the University of Cape Town, Dan Stein, on 
021 – 404 2164 or dan.stein@uct.ac.za , if you have any further queries or encounter any problems. 
You can contact the UCT Faculty of Health Sciences Human Research Ethics Committee at 021 – 
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406 6346 if you have any concerns or complaints that have not been adequately addressed by study 
staff. 
Declaration by participant 
By signing below, I …………………………………..…………. agree to take part in a genetic research 
study entitled Gambling disorder and methamphetamine use disorder: A neurocognitive, 
genetic and neuroimaging study. 
I declare that: 
 
 I have read or had read to me this information and consent form and it is written in a 
language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been adequately 
answered. 
 I understand that taking part in this study is voluntary and I have not been pressurised to 
take part. 
 I have received a signed duplicate copy of this consent form for my records. 
Tick the options that apply: 
 I agree to take part in the study and consent to my blood being drawn. My anonymized 
information and blood sample will be stored and used for the current research project. 
Please destroy my DNA sample as soon as the current research project has been 
completed.   
 
 I agree that my anonymized information and blood or DNA sample can be stored, but I 
can choose to request at any time that my stored sample be destroyed.  I have the right 
to receive confirmation that my request has been carried out.   
 
I agree that my anonymized information and blood or DNA sample can be made available on 
an online database for use by other researchers, but I can choose to request that my stored 
sample be destroyed. I have the right to receive confirmation that my request has been 
carried out. 
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I agree that my anonymized brain imaging information can be made available for use by other 
researchers. 
 
Signed at (place)  ..........................................................  on (date)  .....................................................  
 
 ............................................................................  .........................................................................  
Signature of participant Signature of witness 
Declaration by investigator 
 
I (name) ………………………………………………… declare that: 
 
 I explained the information in this document to …………………..……………... 
 I encouraged him/her to ask questions and took adequate time to answer them. 
 I am satisfied that he/she adequately understands all aspects of the research as 
discussed above. 
 I did/did not use an interpreter.  (If an interpreter is used then the interpreter must sign 
the declaration below). 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. . 
 
 ............................................................................  .........................................................................  
Signature of investigator Signature of witness 
 
Declaration by interpreter 
 
I (name) ………………………………………………… declare that: 
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 I assisted the investigator (name) …………………………. to explain the information in
this document to (name of participant) …………………………….. using the language
medium of Afrikaans/Xhosa. 
 We encouraged him/her to ask questions and took adequate time to answer them.
 I conveyed a factually correct version of what was related to me.
 I am satisfied that the participant fully understands the content of this informed consent
document and has had all his/her question satisfactorily answered.
Signed at (place) ......................…........…………….. on (date) …………....……….. . 
 ............................................................................  .........................................................................  
Signature of interpreter Signature of witness 
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TABLES 
Table 1:  Differences in impulsivity between clusters as measured with the UPPS-P. 
UPPS-P 
Cluster Mean Standard deviation 
“Alcohol cluster” 136.00 24.23 
“Healthy cluster” 136.94 24.10 
“Antisocial cluster” 157.93 17.85 
“Borderline cluster” 152.00 23.93 
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Table 2:  Differences in illness severity between clusters as measured with the Y-BOCS-du. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Measure Cluster 
Total 
score 
(mean) 
Std. 
deviation 
p-value 
Y-BOCS-du 
Cluster 1: Alcohol cluster 27.50 8.78 
0.03 
Cluster 2: Healthy cluster 18.68 9.82 
Cluster 3: Antisocial cluster 23.40 11.30 
Cluster 4: Borderline cluster 27.21 9.62 
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FIGURES 
Figure 1:  Dendrogram (tree-diagram) of 65 cases with Euclidean distances and a linkage distance of 
6.63 that divides the sample into 4 clusters.  The X-axes represents all cases included. 
Figure 2:  Cases clustered according to impulsive comorbidities.  
Figure 3:  Differences in total impulsivity between clusters, as measured with the UPPS-P.  
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Figure 4:  Illness severity between clusters as measured with the Y-BOCS-du 
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